SOLIGENIX, INC.

SOLIGENIX, INC. (SNGX) is a publicly listed company on US equity markets.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

The company reports trailing twelve-month revenue of $119,371 and net loss of $2.82M.

Key metrics include a return on equity of -91.4%, a debt-to-equity ratio of 1.24.

Use FINOTAUR to track SNGX's price action, review fundamentals, and stay current with company news — all in one research dashboard.